Enter inventor name

Yves Girard

This inventor holds 48 USPTO granted patents and 1 published patent application, primarily in PDE4 Inhibitors. Top assignees: Merck Frosst Canada, Inc., Merck + Co., Inc., Merck Frosst Canada & Co.. Active years: 1977-2009.

USPTO Granted Patents = 48 (Patent Applications = 1)

% Patents Active = 83.3

Average Co-Inventor Count = 4.1

ph-index = 12

Forward Citations = 344(Granted Patents)

Location History:

Dollard des Ormeauz, CA (1979)
Dollard des Ormeaux, CA (1977 - 1981)
Pierresfonds, CA (1987)
Pierrsponds, CA (1988)
Pierrefonds, CA (1982 - 1989)
Lle Bizard, CA (1988 - 1992)
Bizard, CA (1990 - 1994)
Quebec, CA (1991 - 2001)
Ille Bizard, CA (1998 - 2004)
L'lle-Bizard, CA (2005)
L'ille Bizard, CA (2001 - 2008)
Ile Bizard, CA (1989 - 2009)

Company Filing History:

32 out of 212

Merck Frosst Canada, Inc.

Merck Frosst Canada & Co.

patents

4. 1 out of 2,405

Merck Sharp + Dohme Corp.

patents

where one patent can have more than one assignee

Years Active: 1977-2009

Loading Chart...

Areas of Expertise:

PDE4 Inhibitors

Quinolinones

Cycloheptindoles

Pharmaceutical Compositions

Leukotriene Biosynthesis

Diphenyl Compounds

Heteroaryl Compounds

Tri-aryl Derivatives

Phenyl Derivatives

Hydroxamic Acids

Naphthalene Lactones

Aryl Compounds

48 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7629467 - Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use (2009-12-08),

2. 7348433 - Quinolinones as prostaglandin receptor ligands (2008-03-25),

3. 7342024 - 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors (2008-03-11),

4. 7238706 - 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors (2007-07-03),

5. 7153968 - 8-(biaryl)quinoline PDE4 inhibitors (2006-12-26),

6. 6919353 - Substituted 8-arylquinolune PDE4 inhibitors (2005-07-19),

7. 6677351 - 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors (2004-01-13),

8. 6448274 - Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor (2002-09-10),

9. 6410563 - Substituted 8-arylquinoline phosphodiesterase-4 inhibitors (2002-06-25),

10. 6204275 - PDE IV inhibiting compounds, compositions and methods of treatment (2001-03-20),

11. 6200993 - Heterosubstituted pyridine derivatives as PDE4 inhibitors (2001-03-13),

12. 6180650 - Heterosubstituted pyridine derivatives as PDE 4 inhibitors (2001-01-30),

13. 5710170 - Tri-aryl ethane derivatives as PDE IV inhibitors (1998-01-20),

14. 5710160 - Diphenyl pyridyl ethane derivatives as PDE IV inhibitors (1998-01-20),

15. 5459271 - Arylbicyclooctanes as inhibitors of leukotriene biosynthesis (1995-10-17),

Title: The Innovative Journey of Yves Girard: Paving the Way for Medical Breakthroughs

Introduction:

Yves Girard, a skilled inventor hailing from Ile-Bizard, Canada, has left a remarkable impact on the field of pharmaceutical advancements. With an impressive number of 48 patents under his name, Girard's contributions have significantly influenced the health and well-being of many.

Latest Patents:

Girard's latest patents showcase his dedication to crafting innovative solutions for various medical conditions. One of his noteworthy inventions includes diphenyl substituted cycloalkanes, which serve as 5-lipoxygenase activating protein inhibitors. These compounds prove valuable as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory, and cyto-protective agents. Additionally, his creation of quinolinones as prostaglandin receptor ligands offers a promising method for treating prostaglandin E mediated diseases effectively.

Career Highlights:

Throughout his career, Yves Girard has made significant strides in the pharmaceutical industry. He has lent his expertise to renowned companies such as Merck Frosst Canada, Inc., and Merck & Company, Inc., where his innovative solutions have contributed to the development of groundbreaking medications.

Collaborations:

In his quest for innovation, Girard has collaborated with remarkable individuals such as Pierre A Hamel and Daniel Dube. Together, they have worked tirelessly to bring forth novel treatments and enhance the field of pharmaceuticals.

Conclusion:

Yves Girard's unwavering commitment to innovation and his relentless pursuit of new solutions have solidified his position as a pioneering figure in the world of pharmaceutical inventions. His contributions continue to inspire and pave the way for future advancements in the medical industry.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]